Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Yehuda Carmeli, M.D.

TitleLecturer on Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Medical Center
Lmob
110 Francis Street
Boston MA 02215
Phone617/632-0761
Fax617/632-0766

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Adler A, Khabra E, Chmelnitsky I, Giakkoupi P, Vatopoulos A, Mathers AJ, Yeh AJ, Sifri CD, De Angelis G, Tacconelli E, Villegas MV, Quinn J, Carmeli Y. Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing Klebsiella pneumoniae clone. Diagn Microbiol Infect Dis. 2014 Jan; 78(1):12-5.
    View in: PubMed
  2. Schwaber MJ, Rubinovitch B, Carmeli Y. Targeted decolonization to prevent ICU infections. N Engl J Med. 2013 Oct 10; 369(15):1470.
    View in: PubMed
  3. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013 Oct; 57(10):5104-11.
    View in: PubMed
  4. Adler A, Solter E, Masarwa S, Miller-Roll T, Abu-Libdeh B, Khammash H, Najem K, Dekadek S, Stein-Zamir C, Nubani N, Kunbar A, Assous MV, Carmeli Y, Schwaber MJ. Epidemiological and Microbiological Characteristics of an Outbreak Caused by OXA-48-Producing Enterobacteriaceae in a Neonatal Intensive Care Unit in Jerusalem, Israel. J Clin Microbiol. 2013 Sep; 51(9):2926-30.
    View in: PubMed
  5. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA. 2013 Apr 3; 309(13):1368-78.
    View in: PubMed
  6. Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ. Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev. 2013 Apr; 26(2):289-307.
    View in: PubMed
  7. Arad E, Navon-Venezia S, Gur E, Kuzmenko B, Glick R, Frenkiel-Krispin D, Kramer E, Carmeli Y, Barnea Y. Novel Rat Model of Methicillin-Resistant Staphylococcus aureus-Infected Silicone Breast Implants: A Study of Biofilm Pathogenesis. Plast Reconstr Surg. 2013 Feb; 131(2):205-14.
    View in: PubMed
  8. Schwaber MJ, Navon-Venezia S, Masarwa S, Tirosh-Levy S, Adler A, Chmelnitsky I, Carmeli Y, Klement E, Steinman A. Clonal transmission of a rare methicillin-resistant Staphylococcus aureus genotype between horses and staff at a veterinary teaching hospital. Vet Microbiol. 2013 Mar 23; 162(2-4):907-11.
    View in: PubMed
  9. Geffen Y, Adler A, Paikin S, Khabra E, Gorenshtein S, Aronov R, Carmeli Y. Detection of the plasmid-mediated KPC-2 carbapenem-hydrolysing enzyme in three unusual species of the Enterobacteriaceae family in Israel. J Antimicrob Chemother. 2013 Mar; 68(3):719-20.
    View in: PubMed
  10. Vervoort J, Baraniak A, Gazin M, Sabirova J, Lammens C, Kazma M, Grabowska A, Izdebski R, Carmeli Y, Kumar-Singh S, Gniadkowski M, Goossens H, Malhotra-Kumar S. Characterization of Two New CTX-M-25-Group Extended-Spectrum ß-Lactamase Variants Identified in Escherichia coli Isolates from Israel. PLoS One. 2012; 7(9):e46329.
    View in: PubMed
  11. Grisaru-Soen G, Friedman T, Dollberg S, Mishali H, Carmeli Y. Late-onset bloodstream infections in preterm infants: A 2-year survey. Pediatr Int. 2012 Dec; 54(6):748-53.
    View in: PubMed
  12. Adler A, Paikin S, Sterlin Y, Glick J, Edgar R, Aronov R, Schwaber MJ, Carmeli Y. A swordless knight: epidemiology and molecular characteristics of the blaKPC-negative sequence type 258 Klebsiella pneumoniae clone. J Clin Microbiol. 2012 Oct; 50(10):3180-5.
    View in: PubMed
  13. Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon BI, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz-Price LS, Carmeli Y, Kaye KS. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-ß-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012 Apr; 56(4):2173-7.
    View in: PubMed
  14. Adler A, Carmeli Y. Dissemination of the Klebsiella pneumoniae carbapenemase in the health care settings: tracking the trails of an elusive offender. MBio. 2011; 2(6).
    View in: PubMed
  15. Adler A, Shklyar M, Schwaber MJ, Navon-Venezia S, Dhaher Y, Edgar R, Solter E, Benenson S, Masarwa S, Carmeli Y. Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism. J Antimicrob Chemother. 2011 Dec; 66(12):2763-6.
    View in: PubMed
  16. Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJ. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 2012 Jan; 39(1):11-5.
    View in: PubMed
  17. Schwaber MJ, Masarwa S, Navon-Venezia S, Kandlik Y, Chmelnitsky I, Smollan G, Glick R, Neria G, Carmeli Y. High prevalence of methicillin-resistant Staphylococcus aureus among residents and staff of long-term care facilities, involving joint and parallel evolution. Clin Infect Dis. 2011 Nov; 53(9):910-3.
    View in: PubMed
  18. Ben-David D, Masarwa S, Navon-Venezia S, Mishali H, Fridental I, Rubinovitch B, Smollan G, Carmeli Y, Schwaber MJ. Carbapenem-resistant Klebsiella pneumoniae in post-acute-care facilities in Israel. Infect Control Hosp Epidemiol. 2011 Sep; 32(9):845-53.
    View in: PubMed
  19. Moran Gilad J, Carmeli Y, Schwartz D, Navon-Venezia S. Laboratory evaluation of the CHROMagar KPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae. Diagn Microbiol Infect Dis. 2011 Aug; 70(4):565-7.
    View in: PubMed
  20. Schechner V, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Finkelstein R, Lachish T, Wiener-Well Y, Alon D, Chowers M, Bardenstein R, Zimhony O, Paz A, Potasman I, Giladi M, Schwaber MJ, Klarfeld-Lidji S, Hochman M, Marchaim D, Carmeli Y. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagn Microbiol Infect Dis. 2011 Sep; 71(1):38-45.
    View in: PubMed
  21. Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis. 2011 Jul; 70(3):367-72.
    View in: PubMed
  22. Hsueh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandria M, Ko WC, Binh TQ. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect. 2011 Aug; 63(2):114-23.
    View in: PubMed
  23. Schechner V, Kotlovsky T, Tarabeia J, Kazma M, Schwartz D, Navon-Venezia S, Carmeli Y. Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter. Infect Control Hosp Epidemiol. 2011 May; 32(5):497-503.
    View in: PubMed
  24. Wernli D, Haustein T, Conly J, Carmeli Y, Kickbusch I, Harbarth S. A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med. 2011 Apr; 8(4):e1001022.
    View in: PubMed
  25. Adler A, Navon-Venezia S, Moran-Gilad J, Marcos E, Schwartz D, Carmeli Y. Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J Clin Microbiol. 2011 Jun; 49(6):2239-42.
    View in: PubMed
  26. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011 Apr 1; 52(7):848-55.
    View in: PubMed
  27. Andremont A, Bonten M, Kluytmans J, Carmeli Y, Cars O, Harbarth S. Fighting bacterial resistance at the root: need for adapted EMEA guidelines. Lancet Infect Dis. 2011 Jan; 11(1):6-8.
    View in: PubMed
  28. Goren MG, Chmelnitsky I, Carmeli Y, Navon-Venezia S. Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel. J Antimicrob Chemother. 2011 Mar; 66(3):672-3.
    View in: PubMed
  29. Shlomai A, Nutman A, Kotlovsky T, Schechner V, Carmeli Y, Guzner-Gur H. Predictors of pandemic (H1N1) 2009 virus positivity and adverse outcomes among hospitalized patients with a compatible syndrome. Isr Med Assoc J. 2010 Oct; 12(10):622-7.
    View in: PubMed
  30. Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Sprecher H, Lachish T, Wiener-Well Y, Alon D, Chowers M, Ciobotaro P, Bardenstein R, Paz A, Potasman I, Giladi M, Schechner V, Schwaber MJ, Klarfeld-Lidji S, Carmeli Y. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2010 Dec; 54(12):5099-104.
    View in: PubMed
  31. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, Gales AC, Venezia SN, Quinn JP, Nordmann P. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis. 2010 Sep; 16(9):1349-56.
    View in: PubMed
  32. Leavitt A, Chmelnitsky I, Carmeli Y, Navon-Venezia S. Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic Klebsiella pneumoniae sequence type 258. Antimicrob Agents Chemother. 2010 Oct; 54(10):4493-6.
    View in: PubMed
  33. Bilavsky E, Schwaber MJ, Carmeli Y. How to stem the tide of carbapenemase-producing enterobacteriaceae?: proactive versus reactive strategies. Curr Opin Infect Dis. 2010 Aug; 23(4):327-31.
    View in: PubMed
  34. de Medina T, Carmeli Y. The pivotal role of long-term care facilities in the epidemiology of Acinetobacter baumannii: another brick in the wall. Clin Infect Dis. 2010 Jun 15; 50(12):1617-8.
    View in: PubMed
  35. Goren MG, Carmeli Y, Schwaber MJ, Chmelnitsky I, Schechner V, Navon-Venezia S. Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient. Emerg Infect Dis. 2010 Jun; 16(6):1014-7.
    View in: PubMed
  36. Leavitt A, Carmeli Y, Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S. Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. Antimicrob Agents Chemother. 2010 Jul; 54(7):3002-6.
    View in: PubMed
  37. Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y. Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. Antimicrob Agents Chemother. 2010 Jun; 54(6):2687-91.
    View in: PubMed
  38. Wener KM, Schechner V, Gold HS, Wright SB, Carmeli Y. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010 May; 54(5):2010-6.
    View in: PubMed
  39. Leavitt A, Chmelnitsky I, Ofek I, Carmeli Y, Navon-Venezia S. Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain. J Antimicrob Chemother. 2010 Feb; 65(2):243-8.
    View in: PubMed
  40. Regev-Yochay G, Raz M, Carmeli Y, Shainberg B, Navon-Venezia S, Pinco E, Leavitt A, Keller N, Rahav G, Malley R, Rubinstein E. Parental Staphylococcus aureus carriage is associated with staphylococcal carriage in young children. Pediatr Infect Dis J. 2009 Nov; 28(11):960-5.
    View in: PubMed
  41. Gottesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis. 2009 Sep 15; 49(6):869-75.
    View in: PubMed
  42. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009 Sep 1; 49(5):682-90.
    View in: PubMed
  43. Schechner V, Straus-Robinson K, Schwartz D, Pfeffer I, Tarabeia J, Moskovich R, Chmelnitsky I, Schwaber MJ, Carmeli Y, Navon-Venezia S. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. J Clin Microbiol. 2009 Oct; 47(10):3261-5.
    View in: PubMed
  44. Chmelnitsky I, Hermesh O, Navon-Venezia S, Strahilevitz J, Carmeli Y. Detection of aac(6')-Ib-cr in KPC-producing Klebsiella pneumoniae isolates from Tel Aviv, Israel. J Antimicrob Chemother. 2009 Oct; 64(4):718-22.
    View in: PubMed
  45. Burgmann H, Stoiser B, Heinz G, Schenk P, Apfalter P, Zedtwitz-Liebenstein K, Frass M, Carmeli Y. Likelihood of inadequate treatment: a novel approach to evaluating drug-resistance patterns. Infect Control Hosp Epidemiol. 2009 Jul; 30(7):672-7.
    View in: PubMed
  46. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009 Aug; 53(8):3365-70.
    View in: PubMed
  47. Benenson S, Navon-Venezia S, Carmeli Y, Adler A, Strahilevitz J, Moses AE, Block C. Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult. Successful treatment with gentamicin and colistin. Int J Infect Dis. 2009 Sep; 13(5):e295-8.
    View in: PubMed
  48. Kanafani ZA, Arduino JM, Muhlbaier LH, Kaye KS, Allen KB, Carmeli Y, Corey GR, Cosgrove SE, Fraser TG, Harris AD, Karchmer AW, Lautenbach E, Rupp ME, Peterson ED, Straus WL, Fowler VG. Incidence of and preoperative risk factors for Staphylococcus aureus bacteremia and chest wound infection after cardiac surgery. Infect Control Hosp Epidemiol. 2009 Mar; 30(3):242-8.
    View in: PubMed
  49. Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health. 2009 Mar-Apr; 12(2):234-44.
    View in: PubMed
  50. Schechner V, Nobre V, Kaye KS, Leshno M, Giladi M, Rohner P, Harbarth S, Anderson DJ, Karchmer AW, Schwaber MJ, Carmeli Y. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis. 2009 Mar 1; 48(5):580-6.
    View in: PubMed
  51. Leavitt A, Chmelnitsky I, Colodner R, Ofek I, Carmeli Y, Navon-Venezia S. Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol. 2009 Apr; 47(4):969-74.
    View in: PubMed
  52. Schwaber MJ, Carmeli Y. The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. Crit Care. 2009; 13(1):106.
    View in: PubMed
  53. Jansen JP, Kumar R, Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics. 2009; 27(12):1045-56.
    View in: PubMed
  54. Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. 2008 Dec 24; 300(24):2911-3.
    View in: PubMed
  55. Navon-Venezia S, Leavitt A, Schwaber MJ, Rasheed JK, Srinivasan A, Patel JB, Carmeli Y. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother. 2009 Feb; 53(2):818-20.
    View in: PubMed
  56. Barnea Y, Carmeli Y, Neville LF, Kahel-Reifer H, Eren R, Dagan S, Navon-Venezia S. Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model. Burns. 2009 May; 35(3):390-6.
    View in: PubMed
  57. Barnea Y, Carmeli Y, Kuzmenko B, Navon-Venezia S. Staphylococcus aureus mediastinitis and sternal osteomyelitis following median sternotomy in a rat model. J Antimicrob Chemother. 2008 Dec; 62(6):1339-43.
    View in: PubMed
  58. Yerushalmy A, Reches A, Lessing JB, Schechner V, Carmeli Y, Grisaru D. Characteristics of microorganisms cultured from infected wounds post-hysterectomy. Eur J Obstet Gynecol Reprod Biol. 2008 Dec; 141(2):169-72.
    View in: PubMed
  59. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, Chawla V, Young JA, Hadley S. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med. 2008 Jul; 36(7):1993-8.
    View in: PubMed
  60. Chmelnitsky I, Navon-Venezia S, Strahilevitz J, Carmeli Y. Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. Antimicrob Agents Chemother. 2008 Aug; 52(8):2962-5.
    View in: PubMed
  61. Navon-Venezia S, Chmelnitsky I, Leavitt A, Carmeli Y. Dissemination of the CTX-M-25 family beta-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel. J Antimicrob Chemother. 2008 Aug; 62(2):289-95.
    View in: PubMed
  62. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008 Apr 15; 46(8):1206-13.
    View in: PubMed
  63. Rotem S, Radzishevsky IS, Bourdetsky D, Navon-Venezia S, Carmeli Y, Mor A. Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J. 2008 Aug; 22(8):2652-61.
    View in: PubMed
  64. Carmeli Y. Strategies for managing today's infections. Clin Microbiol Infect. 2008 Apr; 14 Suppl 3:22-31.
    View in: PubMed
  65. Schwaber MJ, Carmeli Y. Antibiotic therapy in the demented elderly population: redefining the ethical dilemma. Arch Intern Med. 2008 Feb 25; 168(4):349-50.
    View in: PubMed
  66. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother. 2008 Apr; 52(4):1413-8.
    View in: PubMed
  67. Gilad J, Carmeli Y. Treatment options for multidrug-resistant Acinetobacter species. Drugs. 2008; 68(2):165-89.
    View in: PubMed
  68. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008 Mar; 52(3):1028-33.
    View in: PubMed
  69. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008 Mar; 52(3):813-21.
    View in: PubMed
  70. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol. 2007 Oct; 28(10):1121-33.
    View in: PubMed
  71. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007 Nov; 60(5):913-20.
    View in: PubMed
  72. Marchaim D, Navon-Venezia S, Leavitt A, Chmelnitsky I, Schwaber MJ, Carmeli Y. Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital. Infect Control Hosp Epidemiol. 2007 Aug; 28(8):945-50.
    View in: PubMed
  73. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother. 2007 Aug; 51(8):3026-9.
    View in: PubMed
  74. Radzishevsky IS, Rotem S, Bourdetsky D, Navon-Venezia S, Carmeli Y, Mor A. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol. 2007 Jun; 25(6):657-9.
    View in: PubMed
  75. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007 Apr; 59(4):772-4.
    View in: PubMed
  76. Marchaim D, Navon-Venezia S, Schwartz D, Tarabeia J, Fefer I, Schwaber MJ, Carmeli Y. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol. 2007 May; 45(5):1551-5.
    View in: PubMed
  77. Colodner R, Samra Z, Keller N, Sprecher H, Block C, Peled N, Lazarovitch T, Bardenstein R, Schwartz-Harari O, Carmeli Y. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn Microbiol Infect Dis. 2007 Feb; 57(2):201-5.
    View in: PubMed
  78. McKinnon PS, Carter CT, Girase PG, Liu LZ, Carmeli Y. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag Care Interface. 2007 Jan; 20(1):23-34.
    View in: PubMed
  79. Regev-Yochay G, Carmeli Y, Raz M, Pinco E, Etienne J, Leavitt A, Rubinstein E, Navon-Venezia S. Prevalence and genetic relatedness of community-acquired methicillin-resistant Staphylococcus aureus in Israel. Eur J Clin Microbiol Infect Dis. 2006 Nov; 25(11):719-22.
    View in: PubMed
  80. Zimhony O, Chmelnitsky I, Bardenstein R, Goland S, Hammer Muntz O, Navon Venezia S, Carmeli Y. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother. 2006 Sep; 50(9):3179-82.
    View in: PubMed
  81. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2006 Sep; 50(9):3098-101.
    View in: PubMed
  82. Barnea Y, Carmeli Y, Kuzmenko B, Gur E, Hammer-Munz O, Navon-Venezia S. The establishment of a Pseudomonas aeruginosa-infected burn-wound sepsis model and the effect of imipenem treatment. Ann Plast Surg. 2006 Jun; 56(6):674-9.
    View in: PubMed
  83. Barnea Y, Carmeli Y, Gur E, Kuzmenko B, Gat A, Neville LF, Eren R, Dagan S, Navon-Venezia S. Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model. Plast Reconstr Surg. 2006 Jun; 117(7):2284-91.
    View in: PubMed
  84. Kaye KS, Kanafani ZA, Dodds AE, Engemann JJ, Weber SG, Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006 Jun; 50(6):2192-6.
    View in: PubMed
  85. Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, Kaye KS. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2006 May; 50(5):1715-20.
    View in: PubMed
  86. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006 Apr; 50(4):1257-62.
    View in: PubMed
  87. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006 Jan; 50(1):43-8.
    View in: PubMed
  88. Schwaber MJ, Carmeli Y. Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care. 2006; 10(5):164.
    View in: PubMed
  89. Schwaber MJ, Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwartz D, Carmeli Y. Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase production in Enterobacter spp. J Clin Microbiol. 2006 Jan; 44(1):241-3.
    View in: PubMed
  90. Samore MH, Venkataraman L, DeGirolami PC, Merrigan MM, Johnson S, Gerding DN, Carmeli Y, Harbarth S. Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure. Microb Drug Resist. 2006; 12(1):23-8.
    View in: PubMed
  91. Shaked H, Carmeli Y, Schwartz D, Siegman-Igra Y. Enterococcal bacteraemia: epidemiological, microbiological, clinical and prognostic characteristics, and the impact of high level gentamicin resistance. Scand J Infect Dis. 2006; 38(11-12):995-1000.
    View in: PubMed
  92. Samore MH, Lipsitch M, Alder SC, Haddadin B, Stoddard G, Williamson J, Sebastian K, Carroll K, Ergonul O, Carmeli Y, Sande MA. Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. Am J Epidemiol. 2006 Jan 15; 163(2):160-70.
    View in: PubMed
  93. Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, Weber SG. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother. 2005 Nov; 49(11):4555-60.
    View in: PubMed
  94. Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Navon-Venezia S. CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel. Antimicrob Agents Chemother. 2005 Nov; 49(11):4745-50.
    View in: PubMed
  95. Boudewijns M, Vandeven J, Verhaegen J, Ben-Ami R, Carmeli Y. Vitek 2 automated identification system and Kocuria kristinae. J Clin Microbiol. 2005 Nov; 43(11):5832; author reply 5832.
    View in: PubMed
  96. Leibovitz A, Carmeli Y, Segal R. Effect of various antibacterial preparations on the pathogenic oral flora in elderly patients fed via nasogastric tube. Antimicrob Agents Chemother. 2005 Aug; 49(8):3566-8.
    View in: PubMed
  97. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis. 2005 Aug; 18(4):306-13.
    View in: PubMed
  98. Neville LF, Barnea Y, Hammer-Munz O, Gur E, Kuzmenko B, Kahel-Raifer H, Eren R, Elkeles A, Murthy KG, Szabó C, Salzman AL, Dagan S, Carmeli Y, Navon-Venezia S. Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection. Int J Mol Med. 2005 Jul; 16(1):165-71.
    View in: PubMed
  99. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005 May; 49(5):2137-9.
    View in: PubMed
  100. Harris AD, Carmeli Y, Samore MH, Kaye KS, Perencevich E. Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms. Infect Control Hosp Epidemiol. 2005 Apr; 26(4):342-5.
    View in: PubMed
  101. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol. 2005 Apr; 26(4):346-51.
    View in: PubMed
  102. Schlesinger J, Navon-Venezia S, Chmelnitsky I, Hammer-Münz O, Leavitt A, Gold HS, Schwaber MJ, Carmeli Y. Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel. Antimicrob Agents Chemother. 2005 Mar; 49(3):1150-6.
    View in: PubMed
  103. Regev-Yochay G, Rubinstein E, Barzilai A, Carmeli Y, Kuint J, Etienne J, Blech M, Smollen G, Maayan-Metzger A, Leavitt A, Rahav G, Keller N. Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis. 2005 Mar; 11(3):453-6.
    View in: PubMed
  104. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005 Feb; 26(2):166-74.
    View in: PubMed
  105. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2005 Jan; 11(1):22-9.
    View in: PubMed
  106. Navon-Venezia S, Leavitt A, Ben-Ami R, Aharoni Y, Schwaber MJ, Schwartz D, Carmeli Y. Evaluation of an accelerated protocol for detection of extended-spectrum beta-lactamase-producing gram-negative bacilli from positive blood cultures. J Clin Microbiol. 2005 Jan; 43(1):439-41.
    View in: PubMed
  107. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat Rev Microbiol. 2004 Dec; 2(12):979-83.
    View in: PubMed
  108. Regev-Yochay G, Dagan R, Raz M, Carmeli Y, Shainberg B, Derazne E, Rahav G, Rubinstein E. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA. 2004 Aug 11; 292(6):716-20.
    View in: PubMed
  109. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis. 2004 Jun; 10(6):1125-8.
    View in: PubMed
  110. Bolon MK, Wright SB, Gold HS, Carmeli Y. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother. 2004 Jun; 48(6):1934-40.
    View in: PubMed
  111. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis. 2004 May 15; 38(10):1357-63.
    View in: PubMed
  112. Ben-Ami R, Giladi M, Carmeli Y, Orni-Wasserlauf R, Siegman-Igra Y. Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis. 2004 Mar 15; 38(6):843-50.
    View in: PubMed
  113. Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect. 2004 Jan; 10(1):84-5.
    View in: PubMed
  114. Schwaber MJ, Cosgrove SE, Gold HS, Kaye KS, Carmeli Y. Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens. Emerg Infect Dis. 2004 Jan; 10(1):94-9.
    View in: PubMed
  115. Cosgrove SE, Carmeli Y. Studies of bloodstream infection outcomes: reading between the lines. Infect Control Hosp Epidemiol. 2003 Dec; 24(12):884-6.
    View in: PubMed
  116. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis. 2003 Dec 15; 37(12):1629-38.
    View in: PubMed
  117. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis. 2003 Nov; 9(11):1415-22.
    View in: PubMed
  118. Leibovitz A, Dan M, Zinger J, Carmeli Y, Habot B, Segal R. Pseudomonas aeruginosa and the oropharyngeal ecosystem of tube-fed patients. Emerg Infect Dis. 2003 Aug; 9(8):956-9.
    View in: PubMed
  119. Schwaber MJ, Wright SB, Carmeli Y, Venkataraman L, DeGirolami PC, Gramatikova A, Perl TM, Sakoulas G, Gold HS. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis. 2003 Jun; 9(6):657-64.
    View in: PubMed
  120. Ben-Ami R, Navon-Venezia S, Schwartz D, Carmeli Y. Infection of a ventriculoatrial shunt with phenotypically variable Staphylococcus epidermidis masquerading as polymicrobial bacteremia due to various coagulase-negative Staphylococci and Kocuria varians. J Clin Microbiol. 2003 Jun; 41(6):2444-7.
    View in: PubMed
  121. Schwaber MJ, Graham CS, Sands BE, Gold HS, Carmeli Y. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother. 2003 Jun; 47(6):1882-6.
    View in: PubMed
  122. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003 Jun 1; 36(11):1433-7.
    View in: PubMed
  123. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003 Mar 1; 36(5):592-8.
    View in: PubMed
  124. Navon-Venezia S, Hammer-Munz O, Schwartz D, Turner D, Kuzmenko B, Carmeli Y. Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J Clin Microbiol. 2003 Jan; 41(1):155-8.
    View in: PubMed
  125. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003 Jan 1; 36(1):53-9.
    View in: PubMed
  126. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28; 162(19):2223-8.
    View in: PubMed
  127. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis. 2002 Aug; 8(8):802-7.
    View in: PubMed
  128. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2002 Jun; 46(6):1619-28.
    View in: PubMed
  129. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002 Jun 15; 34(12):1558-63.
    View in: PubMed
  130. Navon-Venezia S, Feder R, Gaidukov L, Carmeli Y, Mor A. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother. 2002 Mar; 46(3):689-94.
    View in: PubMed
  131. Carmeli Y, Mozaffari E. Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections. Pharmacotherapy. 2002 Feb; 22(2 Pt 2):55S-62S.
    View in: PubMed
  132. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002 Jan 28; 162(2):185-90.
    View in: PubMed
  133. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis. 2001 Nov 1; 33(9):1462-8.
    View in: PubMed
  134. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001 Sep; 45(9):2628-30.
    View in: PubMed
  135. Carmeli YS, Birenbaum-Carmeli D, Madgar I, Weissenberg R. Donor insemination in Israel. Recipients' choice of donor. J Reprod Med. 2001 Aug; 46(8):757-62.
    View in: PubMed
  136. Harbarth S, Samore MH, Carmeli Y. Antibiotic prophylaxis and the risk of Clostridium difficile-associated diarrhoea. J Hosp Infect. 2001 Jun; 48(2):93-7.
    View in: PubMed
  137. Carmeli YS, Carmeli DB. Donor insemination in Israel: sociodemographic aspects. J Biosoc Sci. 2001 Apr; 33(2):311-4.
    View in: PubMed
  138. Carmeli Y, Castro J, Eliopoulos GM, Samore MH. Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. Antimicrob Agents Chemother. 2001 Jan; 45(1):275-9.
    View in: PubMed
  139. Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC, Quinn JP, Hindler J, Medeiros AA, Bush K. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother. 2000 Nov; 44(11):3035-9.
    View in: PubMed
  140. Harris AD, Samore MH, Nafziger R, DiRosario K, Roghmann MC, Carmeli Y. A survey on handwashing practices and opinions of healthcare workers. J Hosp Infect. 2000 Aug; 45(4):318-21.
    View in: PubMed
  141. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation. 2000 Jun 27; 101(25):2916-21.
    View in: PubMed
  142. Kaye KS, Harris AD, Gold H, Carmeli Y. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Antimicrob Agents Chemother. 2000 Apr; 44(4):1004-9.
    View in: PubMed
  143. Birenbaum-Carmeli D, Carmeli YS, Yavetz H. Secrecy among Israeli recipients of donor insemination. Politics Life Sci. 2000 Mar; 19(1):69-76.
    View in: PubMed
  144. Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis. 2000; 32(6):651-6.
    View in: PubMed
  145. Carmeli YS, Birenbaum-Carmeli D. State regulation of donor insemination: an Israeli case study. Med Law. 2000; 19(4):839-54.
    View in: PubMed
  146. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med. 1999 Nov 8; 159(20):2461-8.
    View in: PubMed
  147. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis. 1999 Oct; 29(4):926-8.
    View in: PubMed
  148. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999 Jun; 43(6):1379-82.
    View in: PubMed
  149. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999 May 24; 159(10):1127-32.
    View in: PubMed
  150. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999 May; 28(5):1128-33.
    View in: PubMed
  151. Troillet N, Carmeli Y, Venkataraman L, DeGirolami P, Samore MH. Epidemiological analysis of imipenem-resistant Serratia marcescens in hospitalized patients. J Hosp Infect. 1999 May; 42(1):37-43.
    View in: PubMed
  152. Troillet N, Carmeli Y, Samore MH, Dakos J, Eichelberger K, DeGirolami PC, Karchmer AW. Carriage of methicillin-resistant Staphylococcus aureus at hospital admission. Infect Control Hosp Epidemiol. 1998 Mar; 19(3):181-5.
    View in: PubMed
  153. Carmeli Y, Eichelberger K, Soja D, Dakos J, Venkataraman L, DeGirolami P, Samore M. Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa. J Clin Microbiol. 1998 Feb; 36(2):595-7.
    View in: PubMed
  154. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 1997 Nov; 25(5):1094-8.
    View in: PubMed
  155. Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis. 1997 Jun; 24(6):1131-4.
    View in: PubMed
  156. Samore M, Lichtenberg D, Saubermann L, Kawachi C, Carmeli Y. A clinical data repository enhances hospital infection control. Proc AMIA Annu Fall Symp. 1997; 56-60.
    View in: PubMed
  157. Birenbaum-Carmeli D, Carmeli YS, Casper RF. Discrimination against men in infertility treatment. J Reprod Med. 1995 Aug; 40(8):590-4.
    View in: PubMed
  158. Carmeli Y, Ruoff KL. Report of cases of and taxonomic considerations for large-colony-forming Lancefield group C streptococcal bacteremia. J Clin Microbiol. 1995 Aug; 33(8):2114-7.
    View in: PubMed
  159. Koren G, Carmeli DB, Carmeli YS, Haslam R. Maturity of children to consent to medical research: the babysitter test. J Med Ethics. 1993 Sep; 19(3):142-7.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Carmeli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_